Trial Profile
A Study Comparing Effectiveness and Safety of Dabigatran and Rivaroxaban In Patients With Atrial Fibrillation Using US Medicare Part D Data.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Oct 2016
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
- Indications Embolism; Stroke
- Focus Adverse reactions; Therapeutic Use
- 29 Oct 2016 New trial record
- 14 Sep 2016 Results published in the American Journal of Cardiovascular Drugs.